Author

Erica Velthuis

Observed names: E. Velthuis, Velthuis, Erica

Institutions: Merck KGaA, Darmstadt (Germany), Merck B.V. (Netherlands)

Observed institutions: Merck KGaA, Darmstadt (Germany), Merck B.V. (Netherlands), Merck Healthcare KGaA, Darmstadt (Germany)

OpenAlex ID: A5017759799

The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

2020 · Erica Velthuis, Julie Hubbard, et al. · Advances in Therapy · 18

Prevention and management of cetuximab-related hypomagnesemia.

2022 · Sabine Tejpar, Hiroya Taniguchi, et al. · Journal of Clinical Oncology · 1

PP01.28: Treatment Sequencing of Tepotinib in Patients With MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Outcomes From ≥3 Years Follow-Up of the VISION Study

2026 · Paul K. Paik, Enriqueta Felip, et al. · Journal of Thoracic Oncology

PP01.23: Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: ≥3-Years Follow-Up of VISION

2026 · Paul K. Paik, Roberto Ferrara, et al. · Journal of Thoracic Oncology

992P Long-term outcomes in Asian patients with MET exon 14 skipping NSCLC receiving tepotinib in the VISION study: ≥3-year follow-up data

2025 · J.C-H. Yang, M. Morise, et al. · Annals of Oncology

Correction to: The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review

2021 · Erica Velthuis, Julie Hubbard, et al. · Advances in Therapy

Works count: 7

Citation count: 19

H-index: 1

I10-index: 1